Compare FTRE & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTRE | ETW |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.4M | 995.8M |
| IPO Year | N/A | N/A |
| Metric | FTRE | ETW |
|---|---|---|
| Price | $14.93 | $9.12 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $11.64 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 284.6K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,759,900,000.00 | N/A |
| Revenue This Year | $3.17 | N/A |
| Revenue Next Year | $0.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $3.97 | $6.96 |
| 52 Week High | $23.22 | $8.49 |
| Indicator | FTRE | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 55.60 |
| Support Level | $14.06 | $9.09 |
| Resistance Level | $14.96 | $9.22 |
| Average True Range (ATR) | 1.02 | 0.08 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 98.26 | 85.45 |
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.